Test page

Home

Discovery

Preclinical

Clinical

Digital

Integrated solutions

NAV Our solutions

Nuvisan story

Our Clients

NAV Our approach

Scientific publications

Brochures

Posters

Videos

Events

NAV Resources

Nuvisan receives US$25 million grant to advance novel non-hormonal contraceptive drug discovery 

The new three-year grant from the Gates Foundation builds on a successful program, delivered over the past three years. It is intended to further expand the pipeline of non-hormonal contraceptive candidates, an area of significant unmet need in global health.

Nuvisan announces the winners of the 3rd Drug Discovery Innovation Challenge 2026

Nuvisan&acute;s Centre of Excellence Discovery in Berlin announces the winners of the 3rd Drug Discovery Innovation Challenge. The Challenge is designed to foster scientific innovation and translational research, with a particular emphasis on supporting start-ups and biotechnology companies developing novel therapeutic approaches in specific disease areas.

Nuvisan joins IHI project LIGAND-AI to help advance AI-driven drug discovery through open science

LIGAND-AI is a new Innovative Health Initiative (IHI) project led by Pfizer and the Structural Genomics Consortium (SGC). This open-science collaboration represents a major step toward the mission of Target 2035 - developing pharmacological modulators for every human protein by 2035.

Simris Biologics selects Nuvisan as CRO for antibody-drug conjugate project

Nuvisan announces rebranding and web redesign

ALS' strategic acquisition drives innovation and science

The global leader in testing, ALS Limited acquired Nuvisan on April 1, 2024, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio. With ALS' commitment to high-quality and personalized solutions spanning from drug discovery to post-commercialization, this strategic acquisition presents specific opportunities for our customers.

Nuvisan is the first Gyrolab® certified CRO in the EU

Since March 2024, Nuvisan has now become the first Gyrolab&reg; certified CRO in the EU.&nbsp;

ALS takes ownership of Nuvisan

With the acquisition of the remaining 51% shares by ALS, we are excited to join the ALS group and contribute to strengthening its pharmaceutical footprint in Europe.

Three years of fruitful collaboration: Nuvisan Berlin and Bayer Pharmaceuticals

Nuvisan announces the first winner of the 1st NUVISAN Drug Discovery Innovation Challenge: ARGO Therapeutics 

Nuvisan Berlin, a fully integrated contract research service provider for drug discovery and development, announced on March 30th the winners of the 1st NUVISAN Drug Discovery Innovation Challenge at the 2nd NUVISAN and VC Forum.

Nuvisan awarded GMP certificate

<span data-contrast="auto" class="TextRun SCXW257279013 BCX8" style="border:0px none #000000;color: #000000; opacity: 1; height: auto; width: auto; margin: 0px; padding: 0px; border-spacing: 0px; list-style-type: disc; list-style-image: none; line-height: 18.3458px;">Mostly used for drug metabolism and pharmacokinetics (DMPK) studies, we are now also able to offer 14C-API manufacturing and quality control in compliance with EU GMP Part-II guidelines

Nuvisan is now a biocrates certified laboratory for MxP® quant 500 kit

For targeted metabolomics assays, we can now provide reproducible analysis for up to 630 metabolites and lipids per biological sample (usually 10 &micro;l is sufficient) including both human and animal plasma, serum, tissue, feces, breast milk, cells and more.

Nuvisan receives $9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines 

Nuvisan&rsquo;s integrated drug discovery expertise leveraged in a grant from the Bill &amp; Melinda Gates Foundation

Test page

Featured stories

ALS takes ownership of Nuvisan

Clinical Pharmacology Unit

Protein Production Pipeline

Other Stories - Nuvisan

TEST CONTACT

Thanks

PROPER CONTACT